Report Overview

The Europe Colorectal Cancer market size stood at around USD 3.28 billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Colorectal cancers are the malignant tumours of the colon and the rectum, which can lead to symptoms like blood in stool, abdominal discomfort, weight loss and more. These usually start by the formation of non-cancerous polyps, which can turn malignant over time. The polyps can be diagnosed by screening.

In Netherlands, colon cancer comes in the top 10 causes of death and disability combined. Even though colon cancer survival has increased in the recent years, Netherlands still has high incidence mortality compared to the surrounding regions. It is surpassed only by Hungary, Norway and Denmark.

In 2017, health care expenditures for colon cancer patients amounted to 597 million euros. This is 0.7% of the total expenditure on Dutch health. 87% of health care expenditure for colon cancer patients went to hospitals in 2017.



 

Market Drivers

The market is expected to be driven by the increased number of colorectal cancer screening tests. In Netherlands, screening for colorectal cancer was started in a phased manner in 2014. It targets individuals aged 55 to 75 years and uses stool test as a screening measure. On January 1, 2020, 82,900 individuals had colorectal cancer. Approximately 15,000 new patients are added each year.

Moreover, the risk of colorectal cancer increases with increasing age. Netherlands is associated with an aging population and this will act a market driver.

The market is also expected to grow due to increasing amount of research and development of new drugs